Search Videos and More
New Guidelines for Radiation Therapy for HPV-associated Head and Neck Cancer
Radiation therapy for HPV-positive oropharyngeal squamous cell carcinoma: An ASTRO clinical practice guidelineAnti-inflammatory Drug Celecoxib Could Reduce Risk of Colon Cancer Recurrence for a Subset of Patients
Review analysis of data from a randomized clinical trial for patients with stage 3 colon cancerAndrew Hantel, MD Reviews Cancer Care and Greenhouse Gases
Telehealth can significantly reduce greenhouse gas emissions from cancer care, with research showing decentralized cancer care and telemedicine can cut emissions 33% compared to traditional in-person visits.Richard Leiter, MD, MA Featured in ASCO Voices
Palliative care physician Richard Leiter, MD, MA, recounts his support of a young patient with end-of-life care and the complexities of communicating with his family.Kenneth Kehl, MD, MPH Reviews Artificial Intelligence and Genomic Data
Using artificial intelligence to link genomic data to clinical outcomes in cancer care across institutions without compromising protected health information is challenging.Jia Luo, MD Discusses NUT Carcinoma
NUT Carcinoma may not be as rare as one thought. Jia Luo, MD, of Dana-Farber, shares new efforts to research this type of rare cancer that can grow anywhere in the body, often in the head, neck and lungs.Lakshmi Nayak, MD Discusses CNS Lymphoma
CNS Lymphoma research at ASCO24: Dana-Farber's Lakshmi Nayak, MD, details findings of a pilot study showing a CAR T-cell therapy has shown promise and is safe and well-tolerated in treating patients with relapsed, treatment-resistant CNS lymphoma.Narjust Florez, MD Discusses Young Lung Cancer
Lung cancer rates in younger adults are rising. Dana-Farber's Narjust Florez, MD discusses research showing that young patients with lung cancer face ample financial toxicity and issues impacting physical, emotional, and functional well-being.Narjust Florez, MD Discusses International Medical Graduate Challenges
1 out of 4 doctors in the United States graduated from international medical schools, yet according to a study presented at ASCO24, these doctors remain victims of discrimination at frequent rates.Ana Garrido-Castro, MD Discusses SACI-IO HR+
Antibody-drug conjugate plus a checkpoint inhibitor shows a trend toward improved survival in PD-L1-positive hormone receptor-positive, HER2-negative breast cancer.Toni Choueiri, MD Discusses Kidney Cancer JAVELIN 101
Kidney cancer research at ASCO24: Final analysis in JAVELIN Renal 101 trial confirms the efficacy and manageable safety profile of avelumab plus axitinib versus sunitinib in patients with advanced kidney cancer. Dana-Farber's Toni Choueiri, MD, explains more.Toni Choueiri, MD Provides Kidney Cancer CLEAR Trial biomarker analysis
Biomarker analysis in the phase 3 CLEAR trial shows biomarkers don't impact the superiority of lenvatinib plus pembrolizumab versus sunitinib as a first-line therapy in patients diagnosed with advanced kidney cancer.